Literature DB >> 31732729

Isolation of Mycobacterium lepromatosis and Development of Molecular Diagnostic Assays to Distinguish Mycobacterium leprae and M. lepromatosis.

Rahul Sharma1, Pushpendra Singh1,2, Rajiv C McCoy3, Shannon M Lenz4, Kelly Donovan5, Maria T Ochoa5, Iris Estrada-Garcia6, Mayra Silva-Miranda7, Fermin Jurado-Santa Cruz8, Marivic F Balagon9, Barbara Stryjewska1, David M Scollard1, Maria T Pena1, Ramanuj Lahiri1, Diana L Williams1, Richard W Truman1, Linda B Adams1.   

Abstract

BACKGROUND: Mycobacterium leprae was thought to be the exclusive causative agent of leprosy until Mycobacterium lepromatosis was identified in a rare form of leprosy known as diffuse lepromatous leprosy (DLL).
METHODS: We isolated M. lepromatosis from a patient with DLL and propagated it in athymic nude mouse footpads. Genomic analysis of this strain (NHDP-385) identified a unique repetitive element, RLPM, on which a specific real-time quantitative polymerase chain reaction assay was developed. The RLPM assay, and a previously developed RLEP quantitative polymerase chain reaction assay for M. leprae, were validated as clinical diagnostic assays according to Clinical Laboratory Improvement Amendments guidelines. We tested DNA from archived histological sections, patient specimens from the United States, Philippines, and Mexico, and US wild armadillos.
RESULTS: The limit of detection for the RLEP and RLPM assays is 30 M. leprae per specimen (0.76 bacilli per reaction; coefficient of variation, 0.65%-2.44%) and 122 M. lepromatosis per specimen (3.05 bacilli per reaction; 0.84%-2.9%), respectively. In histological sections (n = 10), 1 lepromatous leprosy (LL), 1 DLL, and 3 Lucio reactions contained M. lepromatosis; 2 LL and 2 Lucio reactions contained M. leprae; and 1 LL reaction contained both species. M. lepromatosis was detected in 3 of 218 US biopsy specimens (1.38%). All Philippines specimens (n = 180) were M. lepromatosis negative and M. leprae positive. Conversely, 15 of 47 Mexican specimens (31.91%) were positive for M. lepromatosis, 19 of 47 (40.43%) were positive for M. leprae, and 2 of 47 (4.26%) contained both organisms. All armadillos were M. lepromatosis negative.
CONCLUSIONS: The RLPM and RLEP assays will aid healthcare providers in the clinical diagnosis and surveillance of leprosy. © Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  zzm321990 Mycobacterium lepraezzm321990 ; zzm321990 Mycobacterium lepromatosiszzm321990 ; leprosy diagnostic assay; real-time PCR

Year:  2020        PMID: 31732729     DOI: 10.1093/cid/ciz1121

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Fluorescent Hybridization of Mycobacterium leprae in Skin Samples Collected in Burkina Faso.

Authors:  Anselme Millogo; Ahmed Loukil; Mustapha Fellag; Boukary Diallo; Abdoul Salam Ouedraogo; Sylvain Godreuil; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

Review 2.  The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Authors:  Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2020-02-11       Impact factor: 3.131

3.  Construction and Analysis of the Complete Genome Sequence of Leprosy Agent Mycobacterium lepromatosis.

Authors:  Francisco J Silva; Diego Santos-Garcia; Xiaofeng Zheng; Li Zhang; Xiang Y Han
Journal:  Microbiol Spectr       Date:  2022-04-25

4.  A Sensitive and Quantitative Assay to Enumerate and Measure Mycobacterium leprae Viability in Clinical and Experimental Specimens.

Authors:  Jaymes H Collins; Shannon M Lenz; Nashone A Ray; Marivic F Balagon; Deanna A Hagge; Ramanuj Lahiri; Linda B Adams
Journal:  Curr Protoc       Date:  2022-02

Review 5.  Treatment and Evaluation Advances in Leprosy Neuropathy.

Authors:  Gigi J Ebenezer; David M Scollard
Journal:  Neurotherapeutics       Date:  2021-11-19       Impact factor: 7.620

Review 6.  The status Candidatus for uncultured taxa of Bacteria and Archaea: SWOT analysis.

Authors:  Mark J Pallen
Journal:  Int J Syst Evol Microbiol       Date:  2021-09       Impact factor: 2.747

7.  Mycobacterium lepromatosis as Cause of Leprosy, Colombia.

Authors:  Nora Cardona-Castro; María Victoria Escobar-Builes; Héctor Serrano-Coll; Linda B Adams; Ramanuj Lahiri
Journal:  Emerg Infect Dis       Date:  2022-05       Impact factor: 6.883

8.  In silico designing of a recombinant multi-epitope antigen for leprosy diagnosis.

Authors:  Marcela Rezende Lemes; Thaís Cristina Vilela Rodrigues; Arun Kumar Jaiswal; Sandeep Tiwari; Helioswilton Sales-Campos; Leonardo Eurípedes Andrade-Silva; Carlo Jose Freire Oliveira; Vasco Azevedo; Virmondes Rodrigues; Siomar C Soares; Marcos Vinicius da Silva
Journal:  J Genet Eng Biotechnol       Date:  2022-09-02

9.  Simultaneous Determination of Mycobacterium leprae Drug Resistance and Single-Nucleotide Polymorphism Genotype by Use of Nested Multiplex PCR with Amplicon Sequencing.

Authors:  Yasuhisa Iwao; Shuichi Mori; Manabu Ato; Noboru Nakata
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

10.  Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.

Authors:  Shannon M Lenz; Jaymes H Collins; Nashone A Ray; Deanna A Hagge; Ramanuj Lahiri; Linda B Adams
Journal:  PLoS Negl Trop Dis       Date:  2020-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.